Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 17/20 | 0.58 |
| ▸ | ADRB1 | P08588 | 6/20 | 0.58 |
| ▸ | DRD3 | P35462 | 2/20 | 0.57 |
| ▸ | DRD2 | P14416 | 1/20 | 0.57 |
| ▸ | DRD4 | P21917 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9443708 | 1.00 | ADRB3 (0.58) | ADRB3ADRB1DRD3DRD2DRD4 | |
| SCHEMBL5186278 | 1.00 | ADRB3 (0.58) | ADRB3ADRB1DRD3DRD2DRD4 | |
| SCHEMBL5187410 | 1.00 | ADRB3 (0.58) | ADRB3ADRB1DRD3DRD2DRD4 | |
| SCHEMBL9710986 | 1.00 | ADRB3 (0.58) | ADRB3ADRB1DRD3DRD2DRD4 | |
| SCHEMBL9443682 | 1.00 | ADRB3 (0.58) | ADRB3ADRB1DRD3DRD2DRD4 | |
| Hydrochloric Acid SCHEMBL10800181 | 0.99 | ADRB3 (0.57) | ADRB3ADRB1DRD3DRD2DRD4 | |
| Hydrochloric Acid SCHEMBL10803056 | 0.99 | ADRB3 (0.57) | ADRB3ADRB1DRD3DRD2DRD4 | |
| Hydrochloric Acid SCHEMBL9443703 | 0.99 | ADRB3 (0.57) | ADRB3ADRB1DRD3DRD2DRD4 | |
| Hydrochloric Acid SCHEMBL9443731 | 0.99 | ADRB3 (0.57) | ADRB3ADRB1DRD3DRD2DRD4 | |
| Hydrochloric Acid SCHEMBL10800465 | 0.99 | ADRB3 (0.57) | ADRB3ADRB1DRD3DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0966276-B1 | USE OF BETA-3 ADRENERGIC RECEPTOR AGONISTS FOR PREPARING WOUND-HEALING PHARMACEUTICALS | SANOFI SYNTHELABO (FR) | 2003-12-10 | — | — | EP | claimed |
| EP-0211721-B1 | PHENYLETHANOL AMINOTETRALINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI S.A. (FR) | 1989-10-04 | — | — | EP | claimed |
| EP-0318234-A2 | Improvements in or relating to selective serotonin uptake inhibitors | ELI LILLY AND COMPANY (US) | 1989-05-31 | — | — | EP | claimed |
| EP-0211721-A1 | Phenylethanol aminotetralines, process for their preparation and pharmaceutical compositions containing them | SANOFI S.A. (FR) | 1987-02-25 | — | — | EP | claimed |
| EP-1795194-A2 | Use of an antagonist of CB1 receivers associated with a beta3-agonist for preparing medication to be used for treating appetence | Sanofi-Aventis (FR) | 2007-06-13 | — | — | EP | disclosed |
| US-20050026986-A1 | Use of central cannabinoid receptor antagonists for the preparation of drugs | SANOFI-AVENTIS (FR) | 2005-02-03 | — | — | US | disclosed |
| EP-0966276-B1 | USE OF BETA-3 ADRENERGIC RECEPTOR AGONISTS FOR PREPARING WOUND-HEALING PHARMACEUTICALS | SANOFI SYNTHELABO (FR) | 2003-12-10 | — | — | EP | disclosed |
| US-20020128302-A1 | Use of central cannabinoid receptor antagonists for the preparation of drugs | MARUANI JEANNE (FR) | 2002-09-12 | — | — | US | disclosed |
| US-6344474-B1 | Use of central cannabinoid receptor antagonists for regulating appetence | SANOFI-SYNTHELABO (FR) | 2002-02-05 | — | — | US | disclosed |
| US-6235793-B1 | IN DIABETIC MAMMALS | SANOFI-SYNTHELABO (FR) | 2001-05-22 | — | — | US | disclosed |
| EP-0969835-A1 | USE OF CENTRAL CANNABINOID RECEPTOR ANTAGONISTS FOR REGULATING APPETENCE | SANOFI-SYNTHELABO (FR) | 2000-01-12 | — | — | EP | disclosed |
| WO-1998032441-A1 | USE OF CENTRAL CANNABINOID RECEPTOR ANTAGONISTS FOR REGULATING APPETENCE | SANOFI-SYNTHELABO (FR) | 1998-07-30 | — | — | WO | disclosed |
| EP-0211721-B1 | PHENYLETHANOL AMINOTETRALINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI S.A. (FR) | 1989-10-04 | — | — | EP | disclosed |
| EP-0300423-A2 | Cephalosporin compound, method of its production and composition for prevention and treatment of bacterial infectious diseases | Kyoto Pharmaceutical Industries, Ltd. (JP) | 1989-01-25 | — | — | EP | disclosed |
| EP-0211721-A1 | Phenylethanol aminotetralines, process for their preparation and pharmaceutical compositions containing them | SANOFI S.A. (FR) | 1987-02-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026986-A1 | Use of central cannabinoid receptor antagonists for the preparation of drugs | CNR1, CNR2, ADRB3 | ADRB3 3/4885ADRB1 4/4885DRD3 73/4885 |
| US-20020128302-A1 | Use of central cannabinoid receptor antagonists for the preparation of drugs | CNR1, CNR2, GPR119 | ADRB3 4/4885ADRB1 5/4885DRD3 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.